Skip to content

Author

F. Batalini

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.

OBJECTIVE The validity of progression-free survival (PFS) as a surrogate for overall survival (OS) in the antibody-drug conjugate (ADCs) era remains uncertain. We evaluated the association between treatment effects on PFS and OS in randomized trials of ADCs for metastatic breast cancer (mBC) and explored the surrogate...

L. F. Costa de Almeida, A. Cappellaro, M. Noronha et al. · 0 citations
Open access Sep 2026

Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database

Simple Summary Breast cancer is the most common cancer among women, and those carrying inherited mutations in their BRCA1 or BRCA2 genes face a significantly higher lifetime risk of developing the disease. Olaparib, a targeted therapy that blocks proteins that cancer cells rely on for DNA repair, was approved in 2022 f...

F. Batalini, Qi-Xin Li, J. Hayes et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.